REPAIR IMPACT FUND | The COVID-19 pandemic has been a major wakeup call for the world that our battle with infectious diseases is far from over. Drug-resistant bacteria are on a dangerous growth curve – a much slower one than COVID-19, but deadly none the less. Making matters worse, the business model for the development of new antibiotics is broken, and companies that have developed new treatments are going bankrupt. Alex Engel, Partner at Novo Holdings and Director of the REPAIR Impact Fund writes that it is urgent that we recognize the value of anti-infectives to treat drug-resistant bacterial infections, and he calls on governments to move forward with programs that reward value to human health and approval of novel antibiotics rather than the volume of use.